Pitavastatin further decreases serum high-sensitive C-reactive protein levels in hypertensive patients with hypercholesterolemia treated with angiotensin II, type-1 receptor antagonists.
Yoshika
Masamichi
M
Department of Clinical Sciences and Laboratory Medicine, Kansai Medical University, Moriguchi, Japan.
Komiyama
Yutaka
Y
Masuda
Midori
M
Yokoi
Toyohiko
T
Masaki
Hiroya
H
Ohkura
Hiroe
H
Takahashi
Hakuo
H
D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D002097:C-Reactive Protein / Q000032:analysis / Q000187:drug effects*; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D006937:Hypercholesterolemia / Q000188:drug therapy*; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011804:Quinolines / Q000494:pharmacology*; D016896:Treatment Outcome
D047228:Angiotensin II Type 1 Receptor Blockers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011804:Quinolines; D002097:C-Reactive Protein; C108475:pitavastatin